TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Duchenne Muscular Dystrophy Drugs Market Research Report 2023

Global Duchenne Muscular Dystrophy Drugs Market Research Report 2023

  • Category:Life Sciences
  • Published on : 21 December 2022
  • Pages :93
  • Formats:
  • Report Code:SMR-7515878
OfferClick for best price

Best Price: $2320

Duchenne Muscular Dystrophy Drugs Market Size, Share 2022


Market Analysis and Insights: Global Duchenne Muscular Dystrophy Drugs Market

The global Duchenne Muscular Dystrophy Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Duchenne Muscular Dystrophy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Duchenne Muscular Dystrophy Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Duchenne Muscular Dystrophy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Duchenne Muscular Dystrophy Drugs market.

Global Duchenne Muscular Dystrophy Drugs Scope and Market Size

Duchenne Muscular Dystrophy Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2030.

Segment by Type

Molecular-based Therapies

Steroid Therapy

Other

Segment by Application

Hospitals

Clinics

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Biogen

Roche

Daiichi Sankyo

Pfizer

Cumberland Pharmaceuticals

Santhera Pharmaceuticals

Taiho Pharmaceutical

Teijin Pharma

Akashi Therapeutics

Sarepta Therapeutics

BioMarin

Fibrogen Inc

Nobelpharma Co. Ltd

Eloxx Pharmaceuticals

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Duchenne Muscular Dystrophy Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Duchenne Muscular Dystrophy Drugs, with price, sales, revenue, and global market share of Duchenne Muscular Dystrophy Drugs from 2019 to 2022.

Chapter 3, the Duchenne Muscular Dystrophy Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Duchenne Muscular Dystrophy Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Duchenne Muscular Dystrophy Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy Drugs.

Chapter 13, 14, and 15, to describe Duchenne Muscular Dystrophy Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Duchenne Muscular Dystrophy Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Duchenne Muscular Dystrophy Drugs Market Research Report 2023
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 93 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Molecular-based Therapies
1.2.3 Steroid Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2018-2030)
2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Region
2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2018-2023)
2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2030)
2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2018-2023)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2022
3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2018-2023)
4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2030)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2018-2023)
5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2018-2030)
6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023)
6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2018-2030)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023)
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2018-2030)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2018-2030)
9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023)
9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2018-2030)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Detail
11.1.2 Biogen Business Overview
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.1.5 Biogen Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Detail
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.3.5 Daiichi Sankyo Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Detail
11.5.2 Cumberland Pharmaceuticals Business Overview
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.5.5 Cumberland Pharmaceuticals Recent Development
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Detail
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.6.5 Santhera Pharmaceuticals Recent Development
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Detail
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.7.5 Taiho Pharmaceutical Recent Development
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Detail
11.8.2 Teijin Pharma Business Overview
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.8.5 Teijin Pharma Recent Development
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Detail
11.9.2 Akashi Therapeutics Business Overview
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.9.5 Akashi Therapeutics Recent Development
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Detail
11.10.2 Sarepta Therapeutics Business Overview
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.10.5 Sarepta Therapeutics Recent Development
11.11 BioMarin
11.11.1 BioMarin Company Detail
11.11.2 BioMarin Business Overview
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.11.5 BioMarin Recent Development
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Detail
11.12.2 Fibrogen Inc Business Overview
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.12.5 Fibrogen Inc Recent Development
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Detail
11.13.2 Nobelpharma Co. Ltd Business Overview
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.13.5 Nobelpharma Co. Ltd Recent Development
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Detail
11.14.2 Eloxx Pharmaceuticals Business Overview
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
11.14.5 Eloxx Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2030
Table 2. Key Players of Molecular-based Therapies
Table 3. Key Players of Steroid Therapy
Table 4. Key Players of Other
Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2030
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2030
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2018-2023)
Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2030) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2023-2030)
Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy Drugs Market Share by Players (2018-2023)
Table 17. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2022)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2030) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2023-2030)
Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2018-2023)
Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2030) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Application (2023-2030)
Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030) & (US$ Million)
Table 34. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030) & (US$ Million)
Table 36. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 37. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2023-2030) & (US$ Million)
Table 38. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 39. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030) & (US$ Million)
Table 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2030) & (US$ Million)
Table 42. Biogen Company Detail
Table 43. Biogen Business Overview
Table 44. Biogen Duchenne Muscular Dystrophy Drugs Product
Table 45. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 46. Biogen Recent Development
Table 47. Roche Company Detail
Table 48. Roche Business Overview
Table 49. Roche Duchenne Muscular Dystrophy Drugs Product
Table 50. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 51. Roche Recent Development
Table 52. Daiichi Sankyo Company Detail
Table 53. Daiichi Sankyo Business Overview
Table 54. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
Table 55. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 56. Daiichi Sankyo Recent Development
Table 57. Pfizer Company Detail
Table 58. Pfizer Business Overview
Table 59. Pfizer Duchenne Muscular Dystrophy Drugs Product
Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 61. Pfizer Recent Development
Table 62. Cumberland Pharmaceuticals Company Detail
Table 63. Cumberland Pharmaceuticals Business Overview
Table 64. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 65. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 66. Cumberland Pharmaceuticals Recent Development
Table 67. Santhera Pharmaceuticals Company Detail
Table 68. Santhera Pharmaceuticals Business Overview
Table 69. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 70. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 71. Santhera Pharmaceuticals Recent Development
Table 72. Taiho Pharmaceutical Company Detail
Table 73. Taiho Pharmaceutical Business Overview
Table 74. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
Table 75. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 76. Taiho Pharmaceutical Recent Development
Table 77. Teijin Pharma Company Detail
Table 78. Teijin Pharma Business Overview
Table 79. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
Table 80. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 81. Teijin Pharma Recent Development
Table 82. Akashi Therapeutics Company Detail
Table 83. Akashi Therapeutics Business Overview
Table 84. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 85. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 86. Akashi Therapeutics Recent Development
Table 87. Sarepta Therapeutics Company Detail
Table 88. Sarepta Therapeutics Business Overview
Table 89. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 90. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 91. Sarepta Therapeutics Recent Development
Table 92. BioMarin Company Detail
Table 93. BioMarin Business Overview
Table 94. BioMarin Duchenne Muscular Dystrophy DrugsProduct
Table 95. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 96. BioMarin Recent Development
Table 97. Fibrogen Inc Company Detail
Table 98. Fibrogen Inc Business Overview
Table 99. Fibrogen Inc Duchenne Muscular Dystrophy DrugsProduct
Table 100. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 101. Fibrogen Inc Recent Development
Table 102. Nobelpharma Co. Ltd Company Detail
Table 103. Nobelpharma Co. Ltd Business Overview
Table 104. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy DrugsProduct
Table 105. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 106. Nobelpharma Co. Ltd Recent Development
Table 107. Eloxx Pharmaceuticals Company Detail
Table 108. Eloxx Pharmaceuticals Business Overview
Table 109. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy DrugsProduct
Table 110. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2018-2023) & (US$ Million)
Table 111. Eloxx Pharmaceuticals Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2022 VS 2030
Figure 2. Molecular-based Therapies Features
Figure 3. Steroid Therapy Features
Figure 4. Other Features
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application in 2022 & 2030
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2018-2030
Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2030
Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2022 VS 2030
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2022
Figure 14. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2022
Figure 16. North America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 17. North America Duchenne Muscular Dystrophy Drugs Market Share by Country (2018-2030)
Figure 18. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 19. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 20. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 21. Europe Duchenne Muscular Dystrophy Drugs Market Share by Country (2018-2030)
Figure 22. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 23. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 24. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 25. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 26. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 27. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 28. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 29. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Region (2018-2030)
Figure 30. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 31. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 32. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 33. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 34. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 35. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 36. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 37. Latin America Duchenne Muscular Dystrophy Drugs Market Share by Country (2018-2030)
Figure 38. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 39. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Country (2018-2030)
Figure 42. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 43. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 44. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 45. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 46. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 47. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 48. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 49. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 50. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 51. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 52. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 53. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 54. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 55. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 56. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 57. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount